VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC inhibitor Omomyc effectively halts disease progression in metastatic…
Published in the New England Journal of Medicine, results of the phase III EMPOWER trial show improved survival with the…
HER2DX is the world’s first diagnostic test formulated specifically for HER2-positive (HER2+) breast cancer. HER2DX analyzes RNA on 27 genes…
Kidney cancer (KC) ranks 14th in the most common cancers with 431,288 cases in 2020 and an estimated 179,368 deaths…
The next 3-year World Cancer Day (WCD) campaign themed Close the Care Gap kicks off with this year’s global day, 04 February 2022….
For yet another year, researchers from the Vall d’Hebron Institute of Oncology (VHIO), which is part of the Vall d’Hebron…
High-throughput RNA sequencing studies have led to the identification of several long noncoding RNAs (lncRNAs), but without apparent protein-coding roles….
According to a recent report (1) gastric cancer (GC) is responsible for over one million new cases worldwide in 2020, with an…
In her latest ESMO perspectives On target column entitled Food for thought: dietary effects on tumor metabolism & progression, VHIO’s Elena Garralda, Principal…
Published last week in Nature Reviews Disease Primers, a comprehensive review* focused on endometrial cancer (EC) updates on the epidemiology,…
The Center of Excellence Severo Ochoa Award, granted within the subprogram of the Spanish Institutional Strengthening of the State Plan…
Officially launching tomorrow, Thursday 11 November, the next 3-year World Cancer Day (WCD) global campaign (2022-2024) is themed Close the…
